TELOMIR PHARMACEUTICALS INC (TELO) Stock Price, Forecast & Analysis
USA - NASDAQ:TELO - US87975F1049 - Common Stock
TELO Key Statistics, Chart & Performance
The current stock price of TELO is 1.31 USD. In the past month the price decreased by -20.61%. In the past year, price decreased by -68.96%.
TELO Latest News, Press Relases and Analysis
TELO Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 42.04 | 874.88B | ||
| JNJ | JOHNSON & JOHNSON | 17.97 | 449.32B | ||
| MRK | MERCK & CO. INC. | 9.79 | 215.51B | ||
| PFE | PFIZER INC | 7.63 | 138.90B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.12 | 95.03B | ||
| ZTS | ZOETIS INC | 18.97 | 53.29B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.38 | 22.49B | ||
| VTRS | VIATRIS INC | 4.34 | 11.80B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 22.39 | 10.68B | ||
| CORT | CORCEPT THERAPEUTICS INC | 83.77 | 7.77B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 6.89B | ||
| CRNX | CRINETICS PHARMACEUTICALS IN | N/A | 3.77B |
Related stock screener links
About TELO
Company Profile
Telomir Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical company, which focuses on the development and commercialization of TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic treatment for human stem cells. The company is headquartered in Tampa, Florida and currently employs 0 full-time employees. The company went IPO on 2024-02-09. The firm is focused on the development of Telomir-1, a novel small molecule metal ion chelator and regulator designed to lengthen the DNA’s protective telomere caps, which are crucial in the aging process. Telomir 1 is being developed to protect stem cells by elongating and stimulating the telomeres to sustain self-renewal. Telomir-1 helps protect against age-related conditions, including Progeria (a rare genetic disorder that causes rapid aging in children), Wilson’s disease (a genetic disorder leading to toxic copper buildup in the body), and age-related macular degeneration (AMD), as well as Type 2 Diabetes, cancer, and Alzheimer’s disease. The company is exploring the potential of Telomir-1 with ongoing research in animals and then in humans. The company is focused on developing and commercializing TELOMIR-1, proposed to be dosed orally, with the aim of promoting longevity and enhancing overall quality of life.
Company Info
TELOMIR PHARMACEUTICALS INC
900 West Platt Street, Suite 200
Tampa FLORIDA US
Employees: 0
Phone: 18138642562
TELOMIR PHARMACEUTICALS INC / TELO FAQ
Can you describe the business of TELOMIR PHARMACEUTICALS INC?
Telomir Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical company, which focuses on the development and commercialization of TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic treatment for human stem cells. The company is headquartered in Tampa, Florida and currently employs 0 full-time employees. The company went IPO on 2024-02-09. The firm is focused on the development of Telomir-1, a novel small molecule metal ion chelator and regulator designed to lengthen the DNA’s protective telomere caps, which are crucial in the aging process. Telomir 1 is being developed to protect stem cells by elongating and stimulating the telomeres to sustain self-renewal. Telomir-1 helps protect against age-related conditions, including Progeria (a rare genetic disorder that causes rapid aging in children), Wilson’s disease (a genetic disorder leading to toxic copper buildup in the body), and age-related macular degeneration (AMD), as well as Type 2 Diabetes, cancer, and Alzheimer’s disease. The company is exploring the potential of Telomir-1 with ongoing research in animals and then in humans. The company is focused on developing and commercializing TELOMIR-1, proposed to be dosed orally, with the aim of promoting longevity and enhancing overall quality of life.
What is the current price of TELO stock?
The current stock price of TELO is 1.31 USD. The price decreased by -2.96% in the last trading session.
Does TELO stock pay dividends?
TELO does not pay a dividend.
What is the ChartMill rating of TELOMIR PHARMACEUTICALS INC stock?
TELO has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
How is the market expecting TELO stock to perform?
null analysts have analysed TELO and the average price target is 15.81 USD. This implies a price increase of 1106.87% is expected in the next year compared to the current price of 1.31.
What is the GICS sector and industry of TELO stock?
TELOMIR PHARMACEUTICALS INC (TELO) operates in the Health Care sector and the Pharmaceuticals industry.
What is the Price/Earnings (PE) ratio of TELOMIR PHARMACEUTICALS INC (TELO)?
TELOMIR PHARMACEUTICALS INC (TELO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.54).
TELO Technical Analysis
TELO Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to TELO. The financial health of TELO is average, but there are quite some concerns on its profitability.
TELO Financial Highlights
Over the last trailing twelve months TELO reported a non-GAAP Earnings per Share(EPS) of -0.54. The EPS increased by 39.59% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -1945.37% | ||
| ROE | -3353.87% | ||
| Debt/Equity | 0 |
TELO Forecast & Estimates
null analysts have analysed TELO and the average price target is 15.81 USD. This implies a price increase of 1106.87% is expected in the next year compared to the current price of 1.31.